Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06558188 · ClinicalTrials.gov registry record · Phase 4
Combined Anabolic Therapy
A Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06558188: Recruiting Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal, sponsored by Massachusetts General Hospital.
NCT06558188 is a Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06558188, a Phase 4 study of Osteoporosis and Osteoporosis, Postmenopausal, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
Primary Outcome
Change in lumbar spine bone density between month 0 and month 12
Conditions Studied
Interventions
- DRUG Romosozumab
- DRUG Teriparatide
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2027-07-01 |
| Phase | Phase 4 |
What NCT06558188 shows while recruiting
NCT06558188 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Romosozumab is the first listed.
NCT06558188 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06558188 about?
NCT06558188 is a clinical study titled "Combined Anabolic Therapy". In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.
What is the current status of trial NCT06558188?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2025-02-03. Estimated completion is 2027-07-01.
What conditions does trial NCT06558188 study?
This clinical trial studies the following conditions: Osteoporosis, Osteoporosis, Postmenopausal.
What interventions are being tested in trial NCT06558188?
The interventions under investigation include: Romosozumab (DRUG), Teriparatide (DRUG).
Who is sponsoring clinical trial NCT06558188?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06558188 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06558188's enrollment target sits among peer trials
50 57th of 84 higher than 28 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Muscle Impact of Treating Osteoporosis
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI